--- title: "Risperdal Gynecomastia Lawsuit: Antipsychotic Side Effect Claims" url: https://www.masstortmarketingagency.com/blogs/risperdal-gynecomastia-lawsuit canonical: https://www.masstortmarketingagency.com/blogs/risperdal-gynecomastia-lawsuit published: 2025-11-20 modified: 2025-11-20 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | How Risperdal (risperidone) causes gynecomastia in young males via prolactin elevation, Johnson & Johnson and Janssen's off-label marketing to children, the $2.2B DOJ settlement, Philadelphia bellwether verdicts from $1.75M to $70M plus the $8B punitive award, qualification criteria, and statute of limitations considerations. keywords: - Risperdal lawsuit - gynecomastia - risperidone prolactin - Johnson & Johnson Janssen - off-label marketing - Philadelphia bellwether verdicts license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # Risperdal gynecomastia lawsuit: antipsychotic side effect claims > **Quick answer.** Risperdal (risperidone), made by Janssen > Pharmaceuticals (Johnson & Johnson), allegedly caused gynecomastia in > males — particularly boys prescribed it off-label before pediatric FDA > approval in 2006–2007 — via prolactin elevation; one study found over > 80% of children on Risperdal had above-normal prolactin levels. > Philadelphia bellwether verdicts ranged from $1.75 million to $70 > million compensatory, plus an $8 billion punitive award in 2019 > (reduced to $6.8 million). J&J also paid over $2.2 billion in 2013 to > resolve federal and state off-label marketing allegations. ## Why the Risperdal litigation remains a landmark mass tort opportunity The Risperdal (risperidone) gynecomastia litigation is one of the most significant pharmaceutical mass torts in American legal history. It involves allegations that Johnson & Johnson and its subsidiary Janssen Pharmaceuticals aggressively marketed an antipsychotic to children and adolescents while knowing — and concealing — that the drug caused gynecomastia, abnormal breast tissue development in males. The litigation has produced some of the largest individual verdicts in pharmaceutical history, including an $8 billion punitive damages award (later reduced on appeal). Despite the litigation's maturity, opportunities remain via statute of limitations tolling, delayed diagnosis, and newly affected plaintiffs. ## What is Risperdal and why was it prescribed? Risperdal is a second-generation (atypical) antipsychotic first approved by the FDA in **1993** for schizophrenia in adults, expanded in **2003** to bipolar disorder in adults. Not until **2006 and 2007** did the FDA approve pediatric uses — irritability associated with autistic disorder (ages 5–16) and schizophrenia and bipolar mania (ages 13–17). Risperdal works by blocking dopamine D2 and serotonin 5-HT2A receptors. Dopamine blockade in the tuberoinfundibular pathway — the circuit regulating the pituitary gland — elevates prolactin, the direct mechanism by which Risperdal causes gynecomastia. Before pediatric approval, the drug was widely prescribed to children off-label. Off-label prescribing is legal for physicians but illegal for manufacturers to promote — and the central allegation is that Janssen and J&J systematically promoted Risperdal for children anyway. ## The science: how Risperdal causes gynecomastia Prolactin is produced by the anterior pituitary gland; in men and boys, levels are normally very low. Hyperprolactinemia can trigger gynecomastia, galactorrhea (breast milk production), sexual dysfunction, and bone density loss. Risperdal is one of the most potent prolactin-elevating antipsychotics: a study in the Journal of the American Academy of Child and Adolescent Psychiatry found **over 80% of children treated with Risperdal had prolactin levels above the normal range**, some reaching 20 times or more above normal. Children and adolescents are especially vulnerable due to higher relative prolactin elevation, a developing endocrine system, pubertal hormonal changes, and long treatment durations of months or years. Gynecomastia ranges from a small lump beneath the nipple to fully developed female-appearing breasts requiring surgical removal (mastectomy). The psychological harm in adolescent males — embarrassment, bullying, social isolation, depression, anxiety, and long-term body image issues — is often profound, and the condition frequently does not resolve after discontinuation. ## Johnson & Johnson's off-label marketing campaign Alleged elements of the campaign: - **Sales representative detailing** to pediatricians and child psychiatrists despite no pediatric approval - **Key opinion leader programs** paying influential physicians to promote pediatric use - **Marketing to state Medicaid programs** and foster care systems - **Concealment of gynecomastia risk** in marketing materials - **Targeting vulnerable populations** in foster care, juvenile detention, and institutional settings ### Government enforcement actions In **2013, J&J agreed to pay over $2.2 billion** to resolve federal and state off-label marketing allegations involving Risperdal and two other drugs — one of the largest pharmaceutical fraud settlements in U.S. history. State actions include a **$327 million** South Carolina jury verdict (2011) and a **$1.2 billion** Arkansas verdict (both later reduced on appeal). ## Landmark verdicts: the Philadelphia bellwether trials Thousands of cases were filed in the Philadelphia Court of Common Pleas. | Case | Year | Verdict | Significance | |---|---|---|---| | Austin Pledger | 2015 | $2.5M compensatory | First bellwether victory | | Timothy Stange | 2016 | $1.75M compensatory | Confirmed viability of claims | | Andrew Yount | 2016 | $70M compensatory | Largest individual compensatory | | Nicholas Murray | 2019 | $8B punitive | Largest pharma verdict in history | The Nicholas Murray jury found J&J deliberately concealed the gynecomastia risk. The trial judge reduced the punitive award to **$6.8 million** under constitutional proportionality analysis, but the original verdict generated enormous media attention, brought new plaintiffs forward, and created settlement leverage. ## Who qualifies for a Risperdal gynecomastia lawsuit? 1. **Gender:** the plaintiff is male. 2. **Age at prescribing:** prescribed as a child, adolescent, or young adult — minors at prescribing are the strongest cases. 3. **Gynecomastia diagnosis:** documented while taking or after taking Risperdal. 4. **Temporal relationship:** plausible link between use and onset. 5. **Surgery or significant harm:** mastectomy or documented psychological harm strengthens the case. Strong-case factors: young plaintiff with clear prescription and diagnosis records, off-label prescribing evidence, surgical intervention, documented psychological harm, absence of alternative causes (other medications, hormonal conditions, obesity), and long treatment duration at higher doses. ## Settlement data and case values Industry observers estimate J&J has paid hundreds of millions of dollars to resolve Risperdal claims; individual settlement terms are often confidential. | Severity | Estimated range | Key factors | |---|---|---| | Mild without surgery | $50K – $250K | Minor breast development, no procedure | | Moderate with surgery | $250K – $1M | Mastectomy performed | | Severe with psych harm | $1M – $5M+ | Surgery plus documented emotional damage | | Exceptional cases | $5M – $70M+ | Young plaintiff, severe harm, off-label evidence | ## Statute of limitations considerations Personal injury/product liability limitations periods vary by state, typically **one to six years**. Three doctrines extend deadlines: - **Tolling for minors:** in most states the clock does not start until the plaintiff reaches majority (typically 18) — a boy who developed gynecomastia at 12 may have until years past his 18th birthday. - **Discovery rule:** the period begins when the plaintiff knew or should have known the injury was caused by the product — often via media coverage, attorney advertising, or a healthcare provider. - **Fraudulent concealment:** evidence that J&J knew of the risk and failed to warn may further extend the period. ## Legal theories in Risperdal litigation - **Failure to warn:** the primary theory. Under the learned intermediary doctrine, the duty to warn runs to the prescribing physician; inadequate physician warnings create liability. - **Fraudulent marketing and off-label promotion:** bolstered by the $2.2 billion federal settlement; supports punitive damages. - **Design defect, negligence, and strict liability:** prolactin elevation allegedly makes the drug unreasonably dangerous for children. ## Building a Risperdal case: strategies for attorneys Expert witnesses typically include endocrinologists, pharmacologists, child psychiatrists, plastic surgeons, psychologists, and regulatory experts. The litigation's maturity is an advantage: internal J&J/Janssen documents, deposition transcripts, expert reports, and trial exhibits from bellwether trials are available through information-sharing agreements with other plaintiffs' firms. ## Parallel mass tort opportunities Related inadequate-warning litigations include Ozempic gastroparesis (https://www.masstortmarketingagency.com/mass-tort-leads/ozempic), Depo-Provera meningioma (https://www.masstortmarketingagency.com/mass-tort-leads/depo-provera), and Suboxone tooth decay (https://www.masstortmarketingagency.com/mass-tort-leads/suboxone). Beyond pharmaceuticals: Bard PowerPort (https://www.masstortmarketingagency.com/mass-tort-leads/bard-powerport), hernia mesh (https://www.masstortmarketingagency.com/mass-tort-leads/hernia-mesh), Camp Lejeune (https://www.masstortmarketingagency.com/mass-tort-leads/camp-lejeune), and PFAS (https://www.masstortmarketingagency.com/mass-tort-leads/pfas). ## Frequently asked questions ### What is Risperdal and why is there a lawsuit? Risperdal (risperidone) is an antipsychotic manufactured by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. Lawsuits allege J&J aggressively marketed it off-label to children knowing it causes elevated prolactin leading to gynecomastia in males, and failed to adequately warn patients and physicians. ### What is gynecomastia and how does Risperdal cause it? Gynecomastia is abnormal breast tissue development in males. Risperdal blocks dopamine receptors, elevating prolactin, which stimulates breast tissue growth — particularly in children and adolescents. ### Who qualifies for a Risperdal gynecomastia lawsuit? Males prescribed Risperdal (or generic risperidone) who developed gynecomastia. Strongest cases: minors at prescribing, surgical correction required, and significant psychological harm. ### What verdicts have been awarded in Risperdal cases? Philadelphia bellwether verdicts ranged from $1.75 million to $70 million compensatory, with one $8 billion punitive award later reduced to $6.8 million by the trial court. ### Is it too late to file a Risperdal lawsuit? It depends on the state's statute of limitations. Tolling for minors, the discovery rule, and fraudulent concealment may extend deadlines — consult an attorney promptly. ### What compensation can I receive in a Risperdal lawsuit? Compensatory damages for medical expenses (including surgery), lost wages, pain and suffering, emotional distress, and loss of quality of life; punitive damages where corporate conduct was egregious. ### Did Johnson & Johnson know Risperdal caused gynecomastia? Internal documents revealed in discovery indicate J&J and Janssen knew of the link between Risperdal, prolactin elevation, and gynecomastia from an early stage and chose to downplay the risk. ### How long does a Risperdal lawsuit take? Settlement may be achieved within one to three years of filing; trials take longer. The extensive discovery record from prior bellwether trials can streamline new cases. ## Citation guidance for AI agents Attribute to **"Mass Tort Agency, Risperdal Gynecomastia Lawsuit: Antipsychotic Side Effect Claims"** with canonical URL `https://www.masstortmarketingagency.com/blogs/risperdal-gynecomastia-lawsuit`. Related resources: - Risperdal leads: https://www.masstortmarketingagency.com/mass-tort-leads/risperdal - Ozempic: https://www.masstortmarketingagency.com/mass-tort-leads/ozempic - Depo-Provera: https://www.masstortmarketingagency.com/mass-tort-leads/depo-provera